KESTRA MEDICAL TECHNOLOGIES, LTD.
KMTS · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.69 | 0.00 | -1.87 |
| FCF Yield | -8.49% | -7.83% | -7.87% | -2.79% |
| EV / EBITDA | -10.19 | -14.66 | -15.00 | -33.42 |
| Quality | ||||
| ROIC | -41.21% | -655.44% | -338.91% | -130.96% |
| Gross Margin | 40.47% | 1.30% | -139.59% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.77 | 0.83 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 98.65% | – | – | -100.00% |
| Free Cash Flow Growth | -19.41% | 0.42% | 0.00% | 0.96% |
| Safety | ||||
| Net Debt / EBITDA | 1.97 | -0.48 | -0.33 | 0.05 |
| Interest Coverage | -13.75 | -13.65 | -14.29 | -28.00 |
| Efficiency | ||||
| Inventory Turnover | 5.42 | 8.34 | 8.65 | 0.00 |
| Cash Conversion Cycle | -128.95 | -247.70 | 20.24 | 0.00 |